Amplimexon (imexon) / Amplimed Corp - LARVOL DELTA

Identification of differentially expressed autophagy genes associated with osteogenic differentiation in human bone marrow mesenchymal stem cells. (PubMed, Am J Transl Res) - "We identified candidate molecules to further investigate their functions in osteogenesis, providing novel insights into the role of autophagy in mesenchymal stem cell differentiation."

Journal • CD8

A pan-cancer analysis identifies HDAC11 as an immunological and prognostic biomarker. (PubMed, FASEB J) - "In addition, HDAC11 is negatively correlated with the drug sensitivity of oxaliplatin, carmustine, ifosfamide, imexon, lomustine, and BN-2629, indicating the potential synergy between HDAC11 inhibitors and these anti-tumor drugs. HDAC11 is also associated with hallmark pathways, including epithelial mesenchymal transition, IL-6/JAK/STAT3, and allograft rejection pathways. Overall, we provide clues regarding the key role of HDAC11 in multiple cancers."

Biomarker • IO biomarker • Journal • Pan tumor • Immune Modulation • Immunology • Inflammation • Microsatellite Instability • Oncology • Transplant Rejection • HDAC11 • IL6 • MSI • STAT3 • TMB

A pan-cancer analysis of the HER family gene and their association with prognosis, tumor microenvironment, and therapeutic targets. (PubMed, Life Sci) - "These findings may elucidate the roles played by HER family gene in cancer progression and providing insights for further investigation of the HER family gene as potential targets in pan-cancer."

Biomarker • Journal • Pan tumor • Tumor microenvironment • Clear Cell Renal Cell Carcinoma • Head and Neck Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • ERBB3 • ERBB4 • HER-2

Understanding of ROS-Inducing Strategy in Anticancer Therapy. (PubMed, Oxid Med Cell Longev) - "To understand the comprehensive biological response to certain prooxidative anticancer drugs such as 2-methoxyestradiol, buthionine sulfoximine, cisplatin, doxorubicin, imexon, and motexafin gadolinium, we propose and visualize the drug-gene, drug-cell process, and drug-disease interactions involved in oxidative stress induction and antioxidant process inhibition as well as specific side effects of these drugs using pathway analysis with a big data-based text-mining approach. Our review will be helpful to improve the therapeutic effects of anticancer drugs by providing information about biological changes that occur in response to prooxidants. For future directions, there is still a need for pharmacogenomic studies on prooxidative agents as well as the molecular mechanisms underlying the effects of the prooxidants and/or antioxidant-inhibitor agents for effective anticancer therapy through selective killing of cancer cells."

Journal • Review • Oncology

RNA sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB. (PubMed, Cancer Res) - "Gene-drug pairings linked by pathways or functions show specific correlations to isoforms compared with composite gene expression, including ALKBH2-benzaldehyde, AKT3-vandetanib, BCR-imatinib, CDK1 and 20-palbociclib, CASP1-imexon, and FGFR3-pazopanib. Loss of MUC1 20 amino acid variable number tandem repeats, which is used to elicit immune response, and the presence of the androgen receptor AR-V4 and -V7 isoforms in all NCI-60 tissue of origin types demonstrates translational relevance. In summary, we introduce RNA-seq data to our CellMiner and CellMinerCDB web-applications, allowing their exploration for both research and translational purposes."

Journal • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Thoracic Cancer